|
🐜
|
Recommended diagnostic criteria for paraneoplastic neurological syndromes
12 auth.
F. Graus,
J. Delattre,
J. Antoine,
J. Dalmau,
B. Giometto,
W. Grisold,
...
J. Honnorat,
P. Smitt,
C. Vedeler,
J. Verschuuren,
A. Vincent,
R. Voltz
|
10 |
2004 |
10
🐜
|
|
🐢
|
Myasthenia gravis: subgroup classification and therapeutic strategies
N. Gilhus,
J. Verschuuren
|
9 |
2015 |
9
🐢
|
|
🐜
|
Local dystrophin restoration with antisense oligonucleotide PRO051.
16 auth.
J. V. van Deutekom,
A. Janson,
I. Ginjaar,
W. Frankhuizen,
A. Aartsma-Rus,
M. Bremmer-Bout,
J. D. den Dunnen,
K. Koop,
Anneke J van der Kooi,
N. Goemans,
...
S. D. de Kimpe,
P. Ekhart,
E. Venneker,
G. Platenburg,
J. Verschuuren,
G. van Ommen
|
9 |
2007 |
9
🐜
|
|
🐜
|
International consensus guidance for management of myasthenia gravis
15 auth.
D. Sanders,
G. Wolfe,
M. Benatar,
A. Evoli,
N. Gilhus,
I. Illa,
N. Kuntz,
J. Massey,
A. Melms,
H. Murai,
...
M. Nicolle,
Jacqueline A Palace,
D. Richman,
J. Verschuuren,
P. Narayanaswami
|
9 |
2016 |
9
🐜
|
|
🐜
|
Systemic administration of PRO051 in Duchenne's muscular dystrophy.
19 auth.
N. Goemans,
M. Tulinius,
J. T. V. D. van den Akker,
B. Burm,
P. Ekhart,
N. Heuvelmans,
T. Holling,
A. Janson,
G. Platenburg,
J. Sipkens,
...
J. Sitsen,
Annemieke Aartsma-Rus,
G. van Ommen,
G. Buyse,
N. Darín,
J. Verschuuren,
G. Campion,
S. D. de Kimpe,
J. V. van Deutekom
|
9 |
2011 |
9
🐜
|
|
🐜
|
Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations
7 auth.
Annemieke Aartsma-Rus,
I. Fokkema,
J. Verschuuren,
I. Ginjaar,
J. V. van Deutekom,
G. van Ommen,
...
J. D. den Dunnen
|
9 |
2009 |
9
🐜
|
|
🐢
|
Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force
15 auth.
M. Titulaer,
R. Soffietti,
J. Dalmau,
N. Gilhus,
N. Gilhus,
B. Giometto,
F. Graus,
W. Grisold,
J. Honnorat,
P. Smitt,
...
R. Tanasescu,
C. Vedeler,
C. Vedeler,
R. Voltz,
J. Verschuuren
|
8 |
2011 |
8
🐢
|
|
🐜
|
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.
14 auth.
F. Graus,
J. Dalmou,
R. Reñé,
M. Torà,
N. Malats,
J. Verschuuren,
F. Cardenal,
N. Viñolas,
J. G. Muro,
C. Vadell,
...
W. Mason,
R. Rosell,
J. Posner,
F. Real
|
8 |
1997 |
8
🐜
|
|
🐜
|
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
19 auth.
F. Graus,
A. Vogrig,
S. Muñiz-Castrillo,
J. Antoine,
V. Desestret,
D. Dubey,
B. Giometto,
S. Irani,
B. Joubert,
F. Leypoldt,
...
A. McKeon,
H. Prüss,
D. Psimaras,
L. Thomas,
M. Titulaer,
C. Vedeler,
J. Verschuuren,
J. Dalmau,
J. Honnorat
|
8 |
2021 |
8
🐜
|
|
🐜
|
Guidelines for treatment of autoimmune neuromuscular transmission disorders
10 auth.
G. Skeie,
S. Apostolski,
A. Evoli,
N. Gilhus,
I. Illa,
L. Harms,
...
D. Hilton‐Jones,
A. Melms,
J. Verschuuren,
H. W. Horge
|
8 |
2006 |
8
🐜
|
|
🐢
|
Myasthenia gravis
N. Gilhus,
S. Tzartos,
A. Evoli,
Jacqueline A Palace,
T. Burns,
J. Verschuuren
|
8 |
2019 |
8
🐢
|
|
🐢
|
Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies
M. Titulaer,
B. Lang,
J. Verschuuren
|
8 |
2011 |
8
🐢
|
